.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Healthtrust
Fuji
UBS
Fish and Richardson
AstraZeneca
Deloitte
Citi
Johnson and Johnson
Express Scripts

Generated: June 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,752,504

« Back to Dashboard

Which drugs does patent 5,752,504 protect, and when does it expire?


Patent 5,752,504 protects INOMAX and is included in one NDA. There has been one Paragraph IV challenge on INOmax.

Protection for INOMAX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 5,752,504

Title: System for monitoring therapy during calibration
Abstract:A system for continuing the monitoring of certain gases delivered to a patient during the administration of nitric oxide to provide therapy to the patient. The nitric oxide is controlled by a electrically operated valve that is operated by means of an electrical signal from a CPU. At times when the various gas monitors are being calibrated, the normal alarms based upon those gas monitors are conventionally disabled during that calibration time. With the present invention, the electrical signal to the electrically operated valve is detected at the time the system goes into a calibration cycle and that detected electrical signal is used to establish limits such as a upper limit and a lower limit. Therefore, when the electrical signal to the valve is thereafter monitored and its value exceeds either of those limits, the overall nitric oxide delivery system will activate an alarm to alert the user of an abnormal condition. Thus an alarm system is present even when the various gas monitors are otherwise taken out of the system during their calibration.
Inventor(s): Bathe; Duncan P. L. (Madison, WI)
Assignee: Ohmeda Inc. (Liberty Corner, NJ)
Application Number:08/764,569
Patent Claim Types:
see list of patent claims
Device; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Mallinckrodt Hosp
INOMAX
nitric oxide
GAS;INHALATION020845-002Dec 23, 1999DISCNYesNo5,752,504*PED► SubscribeY
Mallinckrodt Hosp
INOMAX
nitric oxide
GAS;INHALATION020845-003Dec 23, 1999RXYesYes5,752,504*PED► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Chubb
McKesson
Express Scripts
Teva
Merck
McKinsey
Harvard Business School
Accenture
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot